The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

With sales of Novo Nordisk ... ($6.2 billion) on similar projects. Meanwhile, thanks to the completion of Novo Holdings’ $16.5 billion Catalent acquisition in December, Novo Nordisk has ...

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

Sales of type 2 diabetes drug Ozempic jumped in 2024 by over a quarter to DKK120.3billion, as human insulin revenues increased by 15 per cent to DKK55.4billion. Consequently, Novo Nordisk's ...

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

REDEFINE 2 is evaluating CagriSema in type 2 diabetes patients who are also either obese or overweight. Novo Nordisk’s CEO Lars Fruergaard Jorgensen said the company “remains confident in ...